We very much appreciate the endorsement of the International Uniform Response Criteria 1 expressed by Prince et al. 2 Their study documents the type of concerns based on which these new criteria were developed collaboratively by investigators from around the world, representing several major myeloma groups. Incorporation of the uniform response criteria in all future myeloma trials will eliminate the serious problem that Prince and co-workers document of markedly different response rates seen in a given trial depending on which of the many existing myeloma-specific response criteria were used to analyze the results.
The rigorous end point of stringent complete response (sCR) in addition to complete response (CR) and very good partial response (VGPR) in the new criteria are particularly important and useful to compare outcomes with novel therapy. We agree that higher levels of response can translate into longer time for progression and improved overall survival. Therefore, precise documentation of higher levels of response (i.e., depth of response) is especially important to allow early detection of potential longer-term benefit.
The new criteria do distinguish relapse from CR from progressive disease for the purposes of calculating time to progression (TTP) and progression free survival (PFS). Relapse from CR is not the end point used to calculate TTP or PFS; instead patients in CR will need to meet criteria for progressive disease for purposes of calculating these end points. There are three reasons for this change. First, relapse from CR is best used when disease free survival is the end point. Second, the test used to define relapse from CR (immunofixation) often fluctuates in a given patient from positive to negative, and is subject to interobserver variation. Third, this change eliminates the potential problem that can occur in future studies as higher CR rates are encountered of ''shorter TTP'' for patients in CR compared to patients who are not in CR, merely based on the inherent variability in the immunofixation results.
More detailed recommendations concerning frequency of disease assessment and other issues as well as protocol selection and entry criteria are ongoing initiatives of the International Myeloma Working Group. Standard induction chemotherapy for acute myeloid leukemia (AML), using cytarabine plus an anthracycline, results in complete remission (CR) in about 55% of patients aged 60 years and over. However, most older patients subsequently relapse, and less than 15% are long-term survivors. 1-3 Patients with poor-risk cytogenetic abnormalities, or secondary AML, have a particularly poor prognosis, with CR rates in the 30% range and virtually no long-term remissions.
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2,3 Many older patients are medically unfit for such aggressive therapy owing to co-morbid medical conditions, or do not wish to receive such therapy. For such patients, the prognosis is bleak; supportive care alone is associated with a median survival of 3-4 months. Relapsed patients also do poorly with low remission rates and short remission duration. 4 There is therefore a clear need for newer active agents in elderly AML patients, particularly those with poor-risk features. Temozolomide (TMZ) is an imidazotetrazine derivative of dacarbazine that functions as an alkylating agent and has high oral bioavailability. In a phase I study in relapsed/refractory AML, the maximum tolerated dose (MTD) was found to be 200 mg/m 2 p.o. daily for 7 days. 5 Of 19 patients treated, four achieved complete clearance of bone marrow blasts. Both induction and post-remission therapy (using 5 days cycles of TMZ) were well tolerated in this study.
One identified mechanism of TMZ resistance is mediated by expression of O 6 -methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme. MGMT-expressing AML cell lines are less sensitive to TMZ; furthermore, transfection of MGMT into sensitive AML cell lines renders the cells resistant to TMZ.
6 Methylation of the MGMT gene promotor region turns off MGMT production, whereas an unmethylated MGMT promotor 
